Re: ZEN-3694 Single Agent Trial Status
posted on
Sep 18, 2017 01:28PM
Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials
Thanks bear for outlining what is known about the trial events. That is very helpful.
I think if there were breakthrough results we'd be receiving updates. I believe this is their first clinical forray into cancer. As you have outlined there are many factors in this trial including maximum dosing, continuous dosing vs intermitant, on it's own vs with enzalutimide, sample size, time, recruiting,etc.
It is never fun to live with mushroom management but that is our situation. If something big was happening we'd know. This is just the beginning of the journey IMHO.
Toinv